Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, Start Printed Page 3504and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel, Drug Development for Opportunistic Infections—Hepatitis C.
Date: February 28—March 1, 2002.
Time: February 28, 2002, 8:30 AM to adjournment.
Agenda: To review and evaluate contract proposals.
Place: 2 Montgomery Village Avenue, Gaithersburg, MD 20879.
Contact Person: Gregory P. Jarosik, PhD, Scientific Review Administrator, Scientific Review Program, Division of Extramural Activities, NIAID, 6700B Rockledge Drive, NMSC-7617, Bethesda, MD 20892, 301-496-2550, email@example.com.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)Start Signature
Dated: January 17, 2002.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 02-1798 Filed 1-23-02; 8:45 am]
BILLING CODE 4140-01-M